Skip to content
Search

Latest Stories

UK’s biggest prostate cancer screening trial to begin next year

UK’s biggest prostate cancer screening trial to begin next year

The trial will be backed by £42 million from the government and Prostate Cancer UK

The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year.


Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK.

The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024.

For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK.

The Department of Health and Social Care (DHSC) believes that thousands of men’s lives could be saved each year if prostate cancer is detected early with effective screening methods.

Health Secretary Victoria Atkins said: “Cancer survival rates continue to improve in the UK, with the disease being diagnosed at an earlier stage more often. But more must be done.

“Our hope is that this funding will help to save the lives of thousands more men through advanced screening methods that can catch prostate cancer as early as possible.”

Laura Kerby, Chief Executive at Prostate Cancer UK, highlighted that each year, 12,000 men die in the UK due to prostate cancer that “doesn’t have a national screening programme.”

TRANSFORM will be the organisation’s “biggest and most ambitious trial ever” and it will “save thousands of men each year.”

“Prostate Cancer UK’s unique focus and expertise made us the only organisation that could really deliver this paradigm-shifting trial, and we’re delighted that the government has backed our vision to revolutionise diagnosis,” she added.

Black men have higher prostate cancer risk

More black men will be invited to participate in the trial, as they are twice more likely to develop prostate cancer than other men.

The DHSC statement read: “1 in 4 black men will develop prostate cancer – double the risk of other men. Therefore, to ensure the trial helps reduce their risk of dying from this disease, 1 in 10 men invited to participate will be black men.”

Men aged 50-75 can participate in the screening trial, with black men eligible from the lower age range of 45-75.

Those at higher risk of prostate cancer due to age and ethnicity will be recruited through their GP practice and invited to a screening visit.

On average, over 52,000 men are diagnosed with prostate cancer every year in the UK, which equals 144 men every day.

Usually, this type of cancer shows no symptoms until it has grown large and become more difficult to treat.

More For You

GPhC should consider reduced fees for pharmacists non-practising practising, says RPS

RPS responds to GPhC consultation on draft changes to fees

gettyimages

RPS urges GPhC to reduce registration fees for non-practising pharmacists

The Royal Pharmaceutical Society (RPS) has called on the General Pharmaceutical Council (GPhC) to reduce annual registration fees for non-practising pharmacists — such as those on parental leave or with a long-term illness — in response to the regulator’s consultation on proposed changes to fees.

The GPhC is proposing a 6% increase in annual registration fees from September 2025 to cover the rising operational costs.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less